These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37314718)

  • 1. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
    Smith B; Engel P; Wu JJ
    N Engl J Med; 2023 Jun; 388(24):2299. PubMed ID: 37314718
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
    Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
    Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Blauvelt A; Thyssen JP; Guttman-Yassky E; Bieber T; Serra-Baldrich E; Simpson E; Rosmarin D; Elmaraghy H; Meskimen E; Natalie CR; Liu Z; Xu C; Pierce E; Morgan-Cox M; Garcia Gil E; Silverberg JI
    Br J Dermatol; 2023 May; 188(6):740-748. PubMed ID: 36994947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply.
    Silverberg JI; Guttman-Yassky E; Gontijo Lima R
    N Engl J Med; 2023 Jun; 388(24):2299-2300. PubMed ID: 37314719
    [No Abstract]   [Full Text] [Related]  

  • 7. Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis.
    Kimura N; Ponda P
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2957-2960. PubMed ID: 37684078
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.
    Prajapati S; Fardos M; Desai AD; Feldman SR
    Immunotherapy; 2023 Sep; 15(13):981-991. PubMed ID: 37401345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Arents BWM
    Br J Dermatol; 2023 May; 188(6):694. PubMed ID: 37094084
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ▼Dupilumab for atopic dermatitis.
    Drug Ther Bull; 2018 Mar; 56(3):30-33. PubMed ID: 29545264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol; 2023 May; 188(6):e43. PubMed ID: 37226395
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.
    Siegfried EC; Igelman S; Jaworski JC; Antaya RJ; Cordoro KM; Eichenfield LF; Levy ML; Paller AS
    Pediatr Dermatol; 2019 Jan; 36(1):172-176. PubMed ID: 30675938
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract]   [Full Text] [Related]  

  • 17. Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab.
    Barroso-García B; Rial MJ; Molina A; Sastre J
    J Investig Allergol Clin Immunol; 2018 Dec; 28(6):420-421. PubMed ID: 30530389
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
    Blakely K; Gooderham M; Papp K
    Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential.
    Vakharia PP; Silverberg JI
    BioDrugs; 2017 Oct; 31(5):409-422. PubMed ID: 28853008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.